Report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Surveillance Subgroup

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue SUPPL. 1, 2007, Pages

  Hayward, Andrew C ^a   Goldsmith, Kim ^a   Johnson, Anne M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Resistance surveillance; Surveillance systems; UK

Indexed keywords

ANTIINFECTIVE AGENT;

ADVISORY COMMITTEE; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG UTILIZATION; HEALTH SURVEY; HUMAN; METHODOLOGY; STATISTICS; UNITED KINGDOM;

ADVISORY COMMITTEES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; GREAT BRITAIN; HUMANS; POPULATION SURVEILLANCE;

EID: 34948855974     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm155     Document Type: Article

References (66)

1. Health Protection Agency. Trends in Antimicrobial Resistance in England and Wales, 2004-2005. www.hpa.org.uk/publications/PublicationDisplay.asp?PublicationID=65 (December 2006).
2. Reporting to the PHLS Communicable Disease Surveillance Centre: A Reference for Laboratories. 2001. PHLS, London.
3. HPA Mandatory. Staphylococcus aureus bacteraemia surveillance scheme. www.hpa.org.uk/infections/topics_az/staphylo/staphylo_mandatory_surveillance.htm (10 June 2007, date last accessed).
4. Mandatory Glycopeptide-Resistant Enterococci (GRE) bacteraemia surveillance. www.hpa.org.uk/infections/topics_az/enterococci/mandatory_surveillance.htm (10 June 2007, date last accessed).
5. Farrell DJ, Morrissey I, De Rubeis D et al. UK Multicentre Study of the Antimicrobial Susceptibility of Bacterial Pathogens Causing Urinary Tract Infection. J Infect 2003; 46: 94-100.
6. Hughes G, Paine T, Thomas D. Surveillance of sexually transmitted infections in England and Wales. Euro Surveill 2001; 6: 71-80.
7. HPA malaria reference unit. www.malaria-reference.co.uk/(10 June 2007, date last accessed).
8. British Society for Antimicrobial Chemotherapy. BSAC website. http://www.bsac.org.uk/resistance_surveillance.cfm (10 June 2007, date last accessed).
9. Reynolds R, Shackcloth J, Felmingham D et al. and BSAC Extended Working Party on Respiratory Resistance Surveillance. Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme. J Antimicrob Chemother 2003; 52: 931-43.
10. European Antimicrobial Resistance Surveillance System website. www.earss.rivm.nl/(10 June 2007, date last accessed).
11. European Committee on Antimicrobial Susceptibility Testing. EUCAST website. http://www.escmid.org/sites/index_f.aspx?par=2.4 (10 June 2007, date last accessed).
12. European Network for Antimicrobial Resistance-ENARE website. http://www.enare.org/(10 June 2007, date last accessed).
13. Fisher IST. International trends in salmonella serotypes 1998-2003-a surveillance report from the Enter-net international surveillance network. Euro Surveill 2004; 9: 45-7.
14. European surveillance network for vigilance against viral resistance (VIRGIL). http://www.virgil-net.org/(10 June 2007, date last accessed).
15. Richet HM, Mohammed J, McDonald LC et al. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 2001; 7: 319-22. 16.
16. Jones RN. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. J Antimicrob Chemother 2000; 46(Suppl. T2): 1-8.
17. Fluit AC, Schmitz FJ, Jones ME et al. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial surveillance program 1997. SENTRY Participants Group. Int J Infect Dis 1999; 3: 153-6.
18. Fluit AC, Jones ME, Schmitz FJ et al. Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. Antonie Van Leeuwenhoek 2000; 77: 147-52.
19. Fluit AC, Wielders CL, Verhoef J et al. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001; 39: 3727-32.
20. Canton R, Morosini M, Enright MC et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinoloneresistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003; 52: 944-52.
21. The Surveillance Networkw (TSNw). Focus/Bio-Inova website. http://www.focusdx.com/bioinova/cms/cms.asp?pid=cms_XIKI33Z0G (10 June 2007, date last accessed).
22. Global Advisory on Antibiotic Resistance Data (GAARD). APUA website. http://www.tufts.edu/med/apua/Miscellaneous/gaard.html (10 June 2007, date last accessed).
23. Alliance for the Prudent use of Antibiotics website. www.tufts. edu/med/apua/(10 June 2007, date last accessed).
24. European Surveillance of Antibiotic Consumption-ESAC website. http://www.esac.ua.ac.be/main.aspx?c=*ESAC2;n=21629 (10 June 2007, date last accessed).
25. Communicable Disease Surveillance Centre, Health Protection Agency: London, UK. 1999/2000 Review of Communicable Diseases, England and Wales. www.hpa.org.uk/infections/publications/1999_2000_review/appendix.pdf (10 June 2007, date last accessed)
26. Communicable Disease Surveillance Centre, Health Protection Agency, London, UK. Specification for Lablink Output to CoSurv (Labmod) and AmSurv. www.hpa.org.uk/infections/about/surveillance/lablink_spec.pdf (2003) (10 June 2007, date last accessed).
27. APICA Project-Automated Pathology Interface for CoSurv and AmSurv. www.hpa.org.uk/infections/topics_az/enterococci/mandatory_surveillance.htm (10 June 2007, date last accessed).
28. Hayward AC et al. Routine National Surveillance of Antibiotic Prescribing for Common Infections using the General Practice Research Database and PACT Data. Final Report to Department of Health. Department of Health, London.
29. O'Neill AJ, Larsen AR, Henriksen AS et al. A fusidic acidresistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob Agents Chemother 2004; 48: 3594-7.
30. Cornaglia G, Hryniewicz W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349-83.
31. Heginbothom ML, Magee JT, Bell JL et al. Welsh Antibiotic Study Group. Laboratory testing policies and their effects on routinesurveillance of community antimicrobial resistance. J Antimicrob Chemother 2004; 53: 1010-7.
32. Magee JT. Effects of duplicate and screening isolates on surveillance of community and hospital antibiotic resistance. J Antimicrob Chemother 2004; 54: 155-62.
33. Gosden PE, Andrews JM, Bowker KE et al. Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society for Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother 1998; 42: 161-9.
34. Potz NA, Mushtaq S, Johnson AP et al. Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method. J Antimicrob Chemother 2004; 53: 729-38.
35. Reynolds R, Shackcloth J, Felmingham D et al. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme. J Antimicrob Chemother 2003; 52: 925-30.
36. Heginbothom ML, Magee JT, Bell JL et al. Laboratory testing policies and their effects on routine surveillance of community antimicrobial resistance. J Antimicrob Chemother 2004; 53: 1010-7.
37. Kahlmeter G, Brown DF, Goldstein FW et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52: 145-8.
38. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001; 48(Suppl. 1): 87-102.
39. Livermore DM, Struelens M, Amorim J et al. Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother 2002; 49: 289-300.
40. Downes A, Thornhill C, Mallard RH. An evaluation of Vitek-an automated system for bacterial identification and susceptibility testing. Commun Dis Public Health 1998; 1: 206-7.
41. Magee JT. Effects of duplicate and screening isolates on surveillance of community and hospital antibiotic resistance. J Antimicrob Chemother 2004; 54: 155-62.
42. Shannon KP, French GL. Validation of the NCCLS proposal to use results only from the first isolate of a species per patient in the calculation of susceptibility frequencies. J Antimicrob Chemother 2002; 50: 965-9.
43. Cebrian L, Rodriguez JC, Escribano I et al. Influence of various criteria for elimination of duplicates when calculating the prevalence and antibiotic susceptibility of microorganisms associated with urinary infections. Int J Antimicrob Agents 2005; 25: 173-6.
44. Huovinen P. Recording of antimicrobial resistance of urinary tract isolates-effect of repeat samples on resistance levels. J Antimicrob Chemother 1985; 16: 443-7.
45. Hayward AC, Goldsmith KA, Islam A et al. Trimethoprim prescribing and antibiotic resistance in urinary coliforms-a data linkage study. DoH Antimicrobial Resistance Research Conference, 29 June 2007. Department of Health, London.
46. Tan TY, McNulty C, Charlett A et al. Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice. J Antimicrob Chemother 2003; 51: 379-84.
47. Connecting for Health. Secondary uses service. www.connectingforhealth. nhs.uk/sus (10 June 2007, date last accessed).
48. Lewis D. Antimicrobial resistance surveillance: methods will depend on objectives. J Antimicrob Chemother 2002; 49: 3-5.
49. Livermore DM, MacGowan AP, Wale MC. Surveillance of antimicrobial resistance. Centralised surveys to validate routine data offer a practical approach. BMJ 1998; 317: 614-5.
50. Oppenheim BA. Surveillance of antibiotic resistance in urinary tract infections-are we misleading prescribers? Commun Dis Public Health 2002; 5: 181-2.
51. McNulty C, Freeman E, Nichols T et al. Laboratory diagnosis of urinary symptoms in primary care-a qualitative study. Commun Dis Public Health 2003; 6: 44-50.
52. McNulty CA, Bowen J, Clark G et al. Microbiology laboratory use. How should general practitioners investigate suspected urinary tract infection? Variations in laboratory-confirmed bacteriuria in South West England. Commun Dis Public Health 2004; 7: 220-6.
53. Smellie WS, Clark G, McNulty CA. Inequalities of primary care microbiology testing between hospital catchment areas. J Clin Pathol 2003; 56: 933-6.
54. Steinke D, Emslie-Smith A, Boyle P et al. A population study of first exposure to community antibacterials in children and the suitability of routine urine samples for study of the acquisition of drug resistance. J Antimicrob Chemother 2002; 50: 1085-8.
55. MacGowan AP, Bowker KE, Bennett PM et al. Surveillance of antimicrobial resistance. Lancet 1998; 352: 1783.
56. Batchelor BI, Crook DW, Jones T et al. Impact of guidelines for the diagnosis of urinary tract infection on trimethoprim susceptibility of Escherichia coli. J Antimicrob Chemother 2002; 49: 223-4.
57. Richards J. Monitoring antibiotic resistance in urinary isolates from the community-a spotter practice model. Commun Dis Pub Health 2002; 5: 226-9.
58. Baerheim A, Digranes A, Hunskarr S. Are resistance patterns in uropathogens published by microbiological laboratories valid for general practice? APMIS 1999; 107: 676-80.
59. Burman WJ, Breese PE, Murray BE et al. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates. Am J Med 2003; 115: 358-64.
60. McNulty CA, Richards J, Livermore DM et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother 2006; 58: 1000-1008.
61. Howard AJ, Magee JT, Fitzgerald KA et al. Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. J Antimicrob Chemother 2001; 47: 305-13.
62. Donnan PT, Wei L, Steinke DT et al. Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data. BMJ 2004; 328: 1297-301.
63. Department of Health. Health Survey for England. www.dh.gov. uk/PublicationsAndStatistics/PublishedSurvey/HealthSurveyForEngland/HealthSurveyBackground/fs/en (10 June 2007, date last accessed).
64. Hay AD, Thomas M, Montgomery A et al. The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data. J Antimicrob Chemother 2005; 56: 146-53.
65. Hospital Episodes Statistics Data. www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=192 (10 June 2007, date last accessed).
66. Hayward A, Petersen I. The Impact of antibiotics on the risk of pneumonia following upper and lower respiratory tract infections. Analysis of the General Practice Research Database-in Health Protection Agency Annual Conference 2006. Health Protection Agency, 2006.